Q-omics provides the consensus-scored CCDC171 profile across patient tissues and cancer cell-line models. CCDC171 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC171 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, CCDC171 RNA expression shows 20,770 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where CCDC171 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC171 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC171 survival associations across molecular data types. CCDC171 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC171 RNA expression–survival associations across cancer types. High CCDC171 expression shows unfavorable associations in KICH, but favorable associations in KIRC, BRCA, READ, CESC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC171 RNA expression.
This table summarizes CCDC171 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC171. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC171 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in LIHC, BLCA and CHOL. The KICH box plot shows higher CCDC171 RNA expression in normal versus tumor tissue (log2 FC = −0.684, t-test p < 0.001).
This table shows molecular features associated with CCDC171 in patient tissues and cancer cell lines. In patient samples, CCDC171 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC171 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
